21:15 , Mar 5, 2019 |  BC Innovations  |  Distillery Techniques

Vascularized kidney organoids for modeling renal disease

TECHNIQUES CATEGORY: Disease models TECHNOLOGY: 3-D models Vascularized kidney organoids could be used to study kidney development and model renal diseases. The organoids are generated in three steps: culturing human pluripotent stem cells with fibroblast...
08:00 , Nov 19, 2015 |  BC Innovations  |  Distillery Techniques

Techniques: Human pluripotent stem cell-derived kidney organoids for in vitro nephrotoxicity screening

Disease models TECHNOLOGY: 3D models Kidney organoids derived from human pluripotent stem cells could be used to screen compounds for nephrotoxicity. Human induced pluripotent stem (iPS) cells or embryonic stem cells (hESCs) sequentially exposed to...
07:00 , Sep 21, 2015 |  BC Week In Review  |  Clinical News

Oral cannabidiol: Phase IIa data

Top-line data from a double-blind, European Phase IIa trial in 88 patients with schizophrenia who inadequately responded to first-line antipsychotic medications showed that twice-daily 500 mg oral GWP42003 as an adjunct treatment met the exploratory...
08:00 , Jan 23, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

Approach Summary Licensing status Publication and contact information Drug platforms Pluripotent cell-derived nephron progenitor cells and self-organizing 3D structures Differentiation of pluripotent cells into nephron progenitors could help model and treat renal diseases. A three-step,...
07:00 , Sep 2, 2013 |  BC Week In Review  |  Clinical News

Nuvigil armodafinil: Phase III data

Teva said it will not proceed with regulatory applications for Nuvigil to treat adults with major depression associated with bipolar I disorder after top-line data from the double-blind, international Phase III Study 3073 in 399...
07:00 , Aug 29, 2013 |  BC Innovations  |  Distillery Techniques

Technology: Disease models

This week in techniques Approach Summary Licensing status Publication and contact information Disease models Mouse model of fibroblast growth factor 9 (Fgf9; Gaf)-driven lung cancer Transgenic mice with inducible expression of Fgf9 in lung epithelium...
07:00 , Jun 27, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Alopecia; hair loss Fibroblast growth factor 9 (FGF9; GAF) Mouse studies suggest FGF9 could help stimulate hair regrowth. In a mouse...
07:00 , Jun 20, 2013 |  BC Innovations  |  Targets & Mechanisms

FGF9 for baldness

A University of Pennsylvania team has found that increasing fibroblast growth factor 9 levels in wounded skin can promote the growth of hair follicles in mice. 1 Follica Inc. has licensed the findings and plans...
08:00 , Jan 28, 2013 |  BC Week In Review  |  Clinical News

Nuvigil armodafinil: Phase III data

Top-line data from the double-blind, international Phase III Study 3072 trial in about 400 patients with major depression associated with bipolar I disorder showed that once-daily 150 mg Nuvigil as adjunctive therapy to mood stabilizers...
07:00 , Apr 28, 2011 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact information Drug platforms Fibroblast growth factor-9 (FGF-9; GAF) delivery for engineering durable blood vessels Studies in mice suggest that FGF-9 could be useful for...